Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03857087 · ClinicalTrials.gov registry record
68Ga-PSMA PET in Diagnosing Metastasis in Patients With Ovarian Cancer
A clinical trial, sponsored by University of California, San Francisco.
- Completed
- Registry status
- 7
- Enrollment target
NCT03857087: Completed study, sponsored by University of California, San Francisco.
NCT03857087 is a clinical trial that has completed, run by University of California, San Francisco. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03857087 has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- 7 participants
- Enrollment target
Study Summary
This trial studies how well gallium Ga 68-labeled prostate specific membrane antigen (PSMA)-11 (68Ga-PSMA) positron emission tomography (PET) works in patients with ovarian cancer to detect whether the tumor has spread to other places in the body. 68Ga-PSMA is a radioactive substance that binds to blood vessels around the ovarian cancer and can be imaged using PET. Diagnostic procedures, such as PET, may help find and diagnose find out how far the disease has spread.
Primary Outcome
Will be descriptively reported for each patient and correlated with the lesions observed in standard imaging computed tomography/magnetic resonance imaging (CT/MRI). In addition, the mean, range, and standard deviation of standardized uptake value maximum (SUVmax) (across all visualized lesions per patient) and SUVmax-average (ave) (across all patients in the study cohort) will be descriptively reported.
Interventions
- PROCEDURE Magnetic Resonance Imaging (MRI)
- PROCEDURE Positron Emission Tomography (PET)
- DRUG Gallium Ga 68-labeled PSMA-11
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2018-04-02 |
| Est. Completion | 2022-06-30 |
What the finished NCT03857087 record still lists
NCT03857087 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 7 participants, a relatively small participant target.
The record links to 0 conditions, and to 3 interventions - of which Magnetic Resonance Imaging (MRI) is the first listed.
NCT03857087 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03857087 about?
NCT03857087 is a clinical study titled "68Ga-PSMA PET in Diagnosing Metastasis in Patients With Ovarian Cancer". This trial studies how well gallium Ga 68-labeled prostate specific membrane antigen (PSMA)-11 (68Ga-PSMA) positron emission tomography (PET) works in patients with ovarian cancer to detect whether the tumor has spread to other places in the body. 68Ga-PSMA is a radioactive substance that binds to b...
What is the current status of trial NCT03857087?
This trial is currently completed. The enrollment target is 7 participants. The study started on 2018-04-02. Estimated completion is 2022-06-30.
What interventions are being tested in trial NCT03857087?
The interventions under investigation include: Magnetic Resonance Imaging (MRI) (PROCEDURE), Positron Emission Tomography (PET) (PROCEDURE), Gallium Ga 68-labeled PSMA-11 (DRUG).
Who is sponsoring clinical trial NCT03857087?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI